Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00053417
Status:
COMPLETED
Last Update Posted:
2011-08-04
First Post:
2003-01-29
Brief Title:
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
Sponsor:
Acorda Therapeutics
Organization:
Acorda Therapeutics
Study Overview
Official Title:
Double-Blind Placebo-Controlled 20-Week Parallel Group Study to Evaluate Safety Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple Sclerosis MS is a disorder of the bodys immune system that affects the Central Nervous System CNS Normally nerve fibers carry electrical impulses through the spinal cord providing communication between the brain and the arms and legs In people with MS the fatty sheath that surrounds and insulates the nerve fibers called myelin deteriorates causing nerve impulses to be slowed or stopped As a result patients with MS may experience periods of muscle weakness and other symptoms such as numbness loss of vision loss of coordination paralysis spasticity mental and physical fatigue and a decrease in the ability to think andor remember These periods of illness may come exacerbations and go remissions Fampridine-SR Sustained Release SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses This study will evaluate the effects of Fampridine-SR on the walking ability of subjects with MS as well as to examine the effects on muscle strength and spasticity The study will also examine the possible risks of taking Fampridine-SR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None